Toll-Interacting Protein in Resolving and Non-Resolving Inflammation

Innate leukocytes manifest dynamic and distinct inflammatory responses upon challenges with rising dosages of pathogen-associated molecular pattern molecules such as lipopolysaccharide (LPS). To differentiate signal strengths, innate leukocytes may utilize distinct intracellular signaling circuitrie...

Full description

Bibliographic Details
Main Authors: Elizabeth J. A. Kowalski, Liwu Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.00511/full
id doaj-5d49cf31549b4c3bbbc6d9353de9375c
record_format Article
spelling doaj-5d49cf31549b4c3bbbc6d9353de9375c2020-11-24T22:38:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-05-01810.3389/fimmu.2017.00511268335Toll-Interacting Protein in Resolving and Non-Resolving InflammationElizabeth J. A. Kowalski0Liwu Li1Department of Biological Sciences, Virginia Polytechnic State University, Blacksburg, VA, USADepartment of Biological Sciences, Virginia Polytechnic State University, Blacksburg, VA, USAInnate leukocytes manifest dynamic and distinct inflammatory responses upon challenges with rising dosages of pathogen-associated molecular pattern molecules such as lipopolysaccharide (LPS). To differentiate signal strengths, innate leukocytes may utilize distinct intracellular signaling circuitries modulated by adaptor molecules. Toll-interacting protein (Tollip) is one of the critical adaptor molecules potentially playing key roles in modulating the dynamic adaptation of innate leukocytes to varying dosages of external stimulants. While Tollip may serve as a negative regulator of nuclear factor κ of activated B cells signaling pathway in cells challenged with higher dosages of LPS, it acts as a positive regulator for low-grade chronic inflammation in leukocytes programmed by subclinical low-dosages of LPS. This review aims to discuss recent progress in our understanding of complex innate leukocyte dynamics and its relevance in the pathogenesis of resolving versus non-resolving chronic inflammatory diseases.http://journal.frontiersin.org/article/10.3389/fimmu.2017.00511/fulllow-grade inflammationtoll-like receptor 4toll-interacting proteinlipopolysaccharidelysosome fusionmitochondria
collection DOAJ
language English
format Article
sources DOAJ
author Elizabeth J. A. Kowalski
Liwu Li
spellingShingle Elizabeth J. A. Kowalski
Liwu Li
Toll-Interacting Protein in Resolving and Non-Resolving Inflammation
Frontiers in Immunology
low-grade inflammation
toll-like receptor 4
toll-interacting protein
lipopolysaccharide
lysosome fusion
mitochondria
author_facet Elizabeth J. A. Kowalski
Liwu Li
author_sort Elizabeth J. A. Kowalski
title Toll-Interacting Protein in Resolving and Non-Resolving Inflammation
title_short Toll-Interacting Protein in Resolving and Non-Resolving Inflammation
title_full Toll-Interacting Protein in Resolving and Non-Resolving Inflammation
title_fullStr Toll-Interacting Protein in Resolving and Non-Resolving Inflammation
title_full_unstemmed Toll-Interacting Protein in Resolving and Non-Resolving Inflammation
title_sort toll-interacting protein in resolving and non-resolving inflammation
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2017-05-01
description Innate leukocytes manifest dynamic and distinct inflammatory responses upon challenges with rising dosages of pathogen-associated molecular pattern molecules such as lipopolysaccharide (LPS). To differentiate signal strengths, innate leukocytes may utilize distinct intracellular signaling circuitries modulated by adaptor molecules. Toll-interacting protein (Tollip) is one of the critical adaptor molecules potentially playing key roles in modulating the dynamic adaptation of innate leukocytes to varying dosages of external stimulants. While Tollip may serve as a negative regulator of nuclear factor κ of activated B cells signaling pathway in cells challenged with higher dosages of LPS, it acts as a positive regulator for low-grade chronic inflammation in leukocytes programmed by subclinical low-dosages of LPS. This review aims to discuss recent progress in our understanding of complex innate leukocyte dynamics and its relevance in the pathogenesis of resolving versus non-resolving chronic inflammatory diseases.
topic low-grade inflammation
toll-like receptor 4
toll-interacting protein
lipopolysaccharide
lysosome fusion
mitochondria
url http://journal.frontiersin.org/article/10.3389/fimmu.2017.00511/full
work_keys_str_mv AT elizabethjakowalski tollinteractingproteininresolvingandnonresolvinginflammation
AT liwuli tollinteractingproteininresolvingandnonresolvinginflammation
_version_ 1725710853187043328